Pay in 4 interest-free payments of $7.47 Learn more
Ships within 48 hours · Estimated delivery Aug 28 - Sep 2
Rat inferior caval vein (ICV) ligature and BPC 157
A landmark study in the Annals of Internal Medicine found that when people are sleep-restricted for just two nights, their Leptin (the fullness hormone) drops by 18%, while Ghrelin (the hunger hormone) spikes by 28%
To view or add a comment, sign in Really interesting paper in JAMA Surgery this week it shows that bariatric surgery is not only more effective and durable for class II and III obesity, but also less expensive than GLP-1 receptor agonists
Aggressive simultaneous protocol (higher risk) Simultaneous start (both from week 1): Tirzepatide standard titration: Same as conservative: 2.5mg 12.5mg over 16 weeks Cagrilintide standard titration (parallel): Weeks 1-4: 0.6mg weekly Weeks 5-8: 1.2mg weekly Weeks 9-12: 1.8mg weekly Week 13+: 2.4mg weekly Aggressive dosing table: Why this is risky: Compounding side effects from start Very difficult to tolerate High dropout risk Unclear if any additional benefit Both hitting stomach simultaneously Potential maximum weight loss: 20-30% body weight (theoretical) Example: 240 lbs 168-192 lbs (48-72 lbs lost) But tolerability extremely questionable Who might attempt: Exceptional GI tolerance Prior success with GLP-1s without nausea Closely monitored by physician Willing to accept high side effect risk Can afford $1,200-2,400/month Understands experimental nature Lower cagrilintide doses with tirzepatide Moderate approach: Tirzepatide: Standard titration to 10-15mg Cagrilintide: Maximum 1.2-1.8mg (lower than standard 2.4mg) Rationale: Tirzepatide doing heavy lifting already Cagrilintide just adds amylin pathway Don't need maximum cagrilintide dose Better tolerability Significantly lower cost Moderate dosing comparison: Verdict: Lower cagrilintide doses (0.6-1.2mg) might be tolerable but benefit questionable
